Imfinzi approval gives AstraZeneca a first immunotherapy combination in early bladder cancer
Imfinzi moves into early bladder cancer, but can AstraZeneca turn a DFS win into real-world bladder-preserving impact?
Why ImmunityBio’s ANKTIVA cost analysis could intensify the bladder cancer value debate
Bladder cancer drugs face a value test. ImmunityBio’s ANKTIVA analysis raises new questions on cost, response durability and access.